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Abstract
Oseltamivir or zanamivir are effective in outpatients with seasonal inﬂuenza; however, factors associated with response have been
incompletely described. During the 2008/2009 epidemic, in a randomized trial for inﬂuenza A-infected outpatients, clinical (time to alle-
viation of ﬂu-related symptoms) and virological (rate of patients with day 2 nasal viral load <200 cgeq/lL) responses to oseltamivir or
zanamivir were assessed and associated factors were determined using multivariate analysis. For oseltamivir (141 patients) and zanamivir
(149 patients) median times to alleviation of symptoms were 3 and 4 days, respectively; 59% and 34% had virological response. For osel-
tamivir, a lower clinical response was associated with female gender (HR, 0.53; 95% CI, 0.36–0.79), baseline symptoms score >14 (HR,
0.47; 0.32–0.70), viral load ‡5 log cgeq/lL (HR, 0.63; 0.43–0.93), and initiation of antibiotics (HR, 0.30; 0.12–0.76); a lower virological
response was associated with female gender (OR, 0.45; 0.21–0.96), baseline viral load ‡5 log cgeq/lL (OR, 0.40; 0.20–0.84) and days 0–
2 incomplete compliance (OR, 0.31; 0.10–0.98). For zanamivir, virological response was associated with age ‡50 years (OR, 0.29; 0.10–
0.85) and initiation of antibiotics at baseline (OR, 4.24; 1.07–17.50). Factors associated with lower response to neuraminidase inhibitors
in outpatients appeared to be easily identiﬁable during routine clinical examination and, when appropriate, by nasal sampling at baseline.
The unknown association between gender and response to oseltamivir was not explained by compliance.
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Introduction
In inﬂuenza-infected patients, recent systematic reviews have
shown that neuraminidase inhibitors reduce the median time
of symptom alleviation in adults and children by approxi-
mately 0.5 day [1–3]. Beyond reducing the duration of the
disease, antivirals have a variable impact on reducing the viral
nasal shedding [4–7].
In 2009 for pandemic A(H1N1) inﬂuenza, the World
Health Organization recommended the use of neuraminidase
inhibitors, oseltamivir or zanamivir, for the treatment of
patients with conﬁrmed or strongly suspected inﬂuenza
infection, when clinical presentation was severe or for
patients in higher risk groups [8]. However, factors inﬂuenc-
ing the clinical and virological responses, which may help
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physicians to detect patients who will get the lowest beneﬁt
from treatment and have to be particularly followed-up, have
been incompletely analysed. Several factors associated with
the clinical response in patients receiving oseltamivir were
identiﬁed in a few studies as: age, high body temperature,
delay from onset to treatment start, inﬂuenza virus type and
infection with an oseltamivir-resistant A(H1N1) virus [9–13].
No speciﬁc study has been conducted to evaluate factors
inﬂuencing the response to zanamivir.
To address these questions, we analysed the data from a
double-blind randomized controlled trial performed during
seasonal inﬂuenza. This trial (Bivir) conducted in France during
the A(H3N2) 2008/2009 epidemic, compared the effectiveness
of an oseltamivir-zanamivir combination with each of the
monotherapies plus placebo. As this trial found an oseltamivir-
zanamivir combination to be less effective than oseltamivir
monotherapy [14], we chose to analyse data collected only
from patients treated with a WHO recommended regimen
(i.e. oseltamivir or zanamivir monotherapy). A better under-
standing of these factors inﬂuencing response to neuramini-
dase inhibitors would provide important insights into the use
of antivirals in future seasonal epidemics or pandemics.
Methods
Recruitment and follow-up of participants
The present study is a secondary analysis of data collected in
the Bivir trial, a community-based randomized trial, con-
ducted between 7 January and 15 March 2009 (period of the
inﬂuenza epidemic in France during the winter 2008–2009),
reported in detail elsewhere [14]. Brieﬂy, patients were
adults over 18 years old who consulted their general practi-
tioner within 36 h of onset of inﬂuenza symptoms and had a
positive nasal rapid test for inﬂuenza A. Exclusion criteria
were: vaccination against inﬂuenza during the 2008–2009 sea-
son; recent exacerbation of COPD; previous history of
depression; and known hypersensitivity to neuraminidase
inhibitors. Patients gave informed written consent to partici-
pate in the study. The protocol was approved by the Ethics
Committee of Ile de France 1.
At enrollment (day 0), a nasal swab for virological analysis
was performed by the general practitioner before initiation
of treatment. In the present study, only day 0 PCR docu-
mented inﬂuenza A-infected patients, allocated to one of the
two oseltamivir or zanamivir monotherapy arms out of three
arms of the Bivir trial, were analysed. Oseltamivir (Roche,
Bale, Switzerland) dosage was 75 mg orally twice daily; za-
namivir dosage was 10 mg by oral inhalation using the com-
mercialized GlaxoSmithKline Diskhaler (GlaxoSmithKline,
Philadelphia, PN, USA), twice daily. The ﬁrst drug administra-
tion was performed in the presence of the general practi-
tioner after the patient had been given instructions on
capsule intake and diskhaler use. Treatments were thereafter
self-administered twice daily for 5 days. A self-administered
questionnaire was given to the patient for self-evaluation of
symptoms and notiﬁcation of drug intake twice daily. A nurse
visited the patients on day 2, performed a nasal swab for
virological analysis between the 4th and 5th drug intake, and
collected data on any adverse event. Patients returned to
their general practitioner 2 days (day 7) after completion of
treatment for follow-up examination and to report any
adverse event. Patients were also contacted by phone on
day 14 to collect data on any further adverse events.
Statistical analysis
As in the main analysis of the Bivir trial [14], clinical
response was assessed as the time to alleviation of inﬂuenza-
related symptoms and virological response as the rate of
patients with, at day 2, a normalized nasal viral load deter-
mined by RT-PCR below 200 cgeq/lL [14].
Factors associated with clinical or virological response
were studied separately for oseltamivir and zanamivir by per-
forming univariate and then multivariate analysis, using Cox
regression for the clinical response and logistic regression
for virological response. The following explanatory variables
were studied: gender, age, smoking status, delay from onset
of any symptom and start of treatment, baseline symptoms
score, baseline fever, baseline physical signs (deﬁned as con-
junctival hyperaemia, erythematous throat, congestive ear-
drum, abnormal chest auscultation, or other), presence at
baseline of at least one co-morbidity, or one clinical compli-
cation, or initiation of antibiotics, type of inﬂuenza virus,
baseline normalized viral load, and full compliance between
day 0 and day 2 (deﬁned as having perfectly taken up the
prescribed treatment during the ﬁrst 2 days of the trial).
From the univariate analyses results, a multivariate model
was built with all variables with p-values <0.10 and then a back-
ward selection approach was used. Then, for each clinical or vi-
rological response outcome, a model with all variables
remaining in the model either for oseltamivir or for zanamivir,
was constructed in order to compare the results of the two
drugs with similar adjustments. All analyses were performed
using SAS software, version 9.2 (SAS Institute, Cary, NC, USA).
Results
Clinical and virological responses were assessed, respectively,
in the 141 and 149 inﬂuenza A-infected outpatients random-
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ized to the oseltamivir and zanamivir monotherapy arms. At
baseline, for oseltamivir and zanamivir, respectively, mean
age was 39.5 and 40.1 years, 52% and 52% were male, and
92% and 87% had H3N2 virus (Table 1). Median times to
alleviation of symptoms were 3 days (interquartile range
(IQR), 2–7) and 4 days (IQR, 2.5–14), respectively. At day 2,
59% and 34% of patients had a viral load <200 cgeq/lL, and
88% and 85% of the patients had full compliance for days 0–
2. A complete description of the patient’s characteristics is
detailed in the main article of the trial [14].
Clinical response
For oseltamivir, in univariate analysis, explanatory variables
with p-values <0.10 were gender, baseline symptoms score
>14, baseline normalized viral load ‡5 log cgeq/lL, initiation
of antibiotics at baseline, and days 0–2 compliance (Table 2).
In the multivariate analysis, a less favourable clinical response
was associated with female gender (HR, 0.53; 95% CI, 0.36–
0.79), baseline symptoms score >14 (HR, 0.47; 0.32–0.70),
baseline normalized viral load ‡5 log cgeq/lL (HR, 0.63;
0.43–0.93), and initiation of antibiotics at baseline (HR, 0.30;
0.12–0.76) (Table 2). Figure 1 presents the time to alleviation
of symptoms in the 141 patients treated with oseltamivir
according to sex and days 0–2 compliance.
For zanamivir, in univariate analysis, explanatory variables
with p-values <0.10 were baseline symptoms score >14 and
presence of physical signs (Table 2). In the multivariate analy-
sis, the clinical response was not associated with any explan-
atory variable (Table 2).
Virological response
For oseltamivir, in univariate analysis, explanatory variables
with p-values <0.10 were gender, baseline normalized viral
load ‡5 log cgeq/lL and compliance between day 0 and day
2 (Table 3). In the multivariate analysis, a less favourable
virological response was associated with female gender (OR,
0.45; 0.21–0.96), baseline normalized viral load ‡5 log cgeq/
lL (OR, 0.40; 0.20–0.84) and days 0–2 incomplete compli-
ance (OR, 0.31; 0.10–0.98) (Table 3).
For zanamivir, in univariate analysis, explanatory variables
with p-values <0.10 were age ‡50, baseline normalized viral
load ‡5 log cgeq/lL, initiation of antibiotics at baseline and
days 0–2 compliance (Table 3). In the multivariate analysis, a
less favourable virological response was associated with age
‡50 years (OR, 0.29; 0.10–0.85), while a more favourable
virological response was associated with an initiation of anti-
biotics at baseline (OR, 4.24; 1.07–17.50) (Table 3).
Discussion
In the present study, various factors appeared to be associ-
ated with the clinical and/or virological responses to neur-
aminidase inhibitors in the context of the 2008/2009
seasonal inﬂuenza, mainly due to H3N2 viruses. Most were
clinically relevant data such as: gender, age, baseline score of
symptoms, prescription of antibiotics, and compliance. One
item of virologically relevant information, nasal viral load at
baseline, appears to be independently associated with the
response. Different associations of these factors were found
depending on the antiviral drug and on whether the clinical
or virological response was considered.
Three types of factors were associated with either the
clinical or the virological response to oseltamivir: compliance,
gender and intensity of the disease, none of these having
been previously reported in the literature, possibly because
they were not tested. It is a hypothesis that the particular
context of a therapeutic trial, with systematic recording of
TABLE 1. Baseline characteristics of the 290 inﬂuenza A-infected patients enrolled in the study according to treatment arms
Oseltamivir, n = 141 Zanamivir, n = 149
Age (years), mean (SD) 39.5 (13.0) 40.1 (14.1)
[Age range] [18.1; 76.3] [18.0; 84.2]
Female, n (%) 68 (48.2) 72 (48.3)
Smoker, n (%) 15 (10.7) 20 (13.4)
Comorbidities, n (%) 20 (14.2) 20 (13.4)
Fever ‡38C at enrollment, n (%) 95 (70.9) 104 (75.9)
Initiation of treatment £24 h after onset of symptoms (%) 68 (48.2) 86 (57.7)
Time of initiation of treatment after onset of symptoms (hours), mean (SD) 25.4 (10.7) 24.4 (10.8)
Symptoms score per patienta,
mean (SD) 15.3 (3.2) 15.5 (3.1)
% of maximal scoreb, mean (SD) 72.7 (15.2) 73.8 (15.0)
Inﬂuenza virus subtype, n (%)
H1N1 5 (3.5) 7 (4.7)
H3N2 130 (92.2) 129 (86.6)
Not determined 6 (4.3) 13 (8.7)
Viral load (log cgeq/lL), mean (SD) 4.5 (1.33) 4.3 (1.43)
aSum of the severity of the seven day 0 inﬂuenza symptoms (feverishness, nasal stufﬁness, sore throat, cough, muscle aches, tiredness-fatigue, and headache) using a four-point
scale [5].
bThe score is expressed as a percentage of the maximal score of 21.
198 Clinical Microbiology and Infection, Volume 19 Number 2, February 2013 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 196–203
detailed clinical and virological data, may have favoured their
detection. The lower response in less compliant patients is
expected, as previously reported in chronic diseases [15–17],
although less frequently assessed in acute situations of infec-
tion. It conﬁrms, if necessary, the clear efﬁciency of oseltami-
vir. In contrast, the less favourable both clinical and
virological responses in women are not usually described. In
contrast to what has been suggested in some other studies
[18,19], the effect of gender in the present study was not
found to be associated with compliance (no interaction with
compliance in the model and no signiﬁcant difference
between men and women for compliance, data not shown)
(Fig. 1). Similar results were obtained in another study, which
found that male gender and low adherence to treatment
were negatively and independently associated with hyperten-
sion control [20]. The role of endocrinological characteristics
has been advocated to inﬂuence the immune response
[21,22]; it cannot be here investigated due to the lack of
such information available in the database of the trial. The
fact that gender was not associated with the response to za-
namivir may suggest that its impact on the response to osel-
tamivir is speciﬁc to some pharmacological characteristics
that differ between the two drugs. Indeed, unlike zanamivir,
which is delivered as the active compound, oseltamivir is
delivered as an inactive prodrug. After oral administration,
oseltamivir is readily absorbed from the gastrointestinal tract
and extensively converted in the liver to the active metabo-
lite, oseltamivir carboxylate, by an esterase [23]. OneT
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FIG. 1. Proportion of the 141 inﬂuenza A-infected patients with alle-
viation of symptoms when treated with oseltamivir plus placebo
according to sex (female dark lines, male grey lines) and days 0–2
compliance (full compliance continuous lines, incomplete compliance
dotted lines). Alleviation of symptoms deﬁned by the presence of no
symptoms of nasal stufﬁness, sore throat, cough, muscle aches, tired-
ness-fatigue, feverishness, and headache or only mild ones, for at
least 24 h.
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hypothesis could thus be a gender difference during the
hepatic process of oseltamivir transformation into the active
compound, which seems to be more active in men compared
with women, as suggested in one previous publication [24].
In an animal model, with another drug, indinavir, such an
inﬂuence of the differential status of an enzyme involved in
the metabolism of the drug has been described between
men and women [25]. Another hypothesis for the lower clin-
ical response to oseltamivir might be that women would
declare a higher intensity of symptoms in the course of the
disease [26]. However, such a hypothesis would not explain
the inﬂuence of gender on the virological component of the
response. Whether the severity of the symptom at baseline
was different in men and women was assessed in the study
and found not to be different (data not shown). If this associ-
ation is conﬁrmed by other studies, it might lead to the
proposition that dosage of oseltamivir should be adjusted in
women, to achieve similar efﬁcacy as in men. This could
prove of importance in patients with complicated or severe
inﬂuenza, including when i.v. administration is needed. This
study also found that the more severe the disease, as sug-
gested by symptom score and viral load at baseline, the
lower the clinical and virological responses in patients trea-
ted with oseltamivir. This corroborates previous results
showing that higher fever was associated with a lower
response rate [9,27]. Even if it seems logical, this had not
been clearly demonstrated for virological determinants,
maybe also because quantitative assessment of viral load by
real-time RT-PCR has been introduced only recently and has
not been used extensively in such a trial design.
It is noteworthy that a limited number of studies have
assessed speciﬁcally which factors were associated with the
response to zanamivir. In the present study, no variables
were found to inﬂuence signiﬁcantly the clinical response to
zanamivir. The only factor associated with a poor virological
response to zanamivir was older age. The effect of age has
already been reported for clinical response to oseltamivir in
two previous studies, but not for zanamivir. In one study,
oseltamivir appeared clinically less effective in young children,
between 0 and 6 years, compared with patients aged 16–
64 years [28]. In the other study, which included children
between 1 and 12 years, a similar effect was observed [27].
Because patients younger than 18 were not included in the
Bivir trial, this association with younger age cannot be
assessed in our study. Whether older people in the Bivir trial
would have had more difﬁculties in using the Diskhaler
device required for delivery of zanamivir remains a question.
Initiation of antibiotics at baseline was the only factor for
which the association was in the opposite direction for osel-
tamivir and zanamivir. Such a factor has not been studied inT
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previous publications, and the limited number of patients
given antibiotics in our study makes interpretation of these
data hazardous. One could suggest that for oseltamivir
response it might be considered as a proxy for the intensity
of the disease at baseline, as were symptom scores and viral
load. It is less easy to explain the positive effect of antibiotics
at baseline on the response to zanamivir. It may be more
directly related to the antibacterial effect; a hypothesis would
be that, in reducing the possible bacterial co-infection, antibi-
otic treatment would allow more efﬁcient local diffusion and
action of the antiviral drug.
We must recognize several limitations to this study. The
presence of a control placebo group might have been help-
ful to distinguish factors associated with the natural history
of the inﬂuenza infection and those truly linked to the
response to antiviral treatment. This choice of a no pla-
cebo-placebo group in the Bivir trial was based on the fol-
lowing reasons: (i) it is proved that neuraminidase inhibitors
reduce the median time of symptom alleviation in adults
and children by approximately 0.5 days, and have a variable
impact on reducing the viral nasal shedding; and (ii) neur-
aminidase inhibitors are recommended in France to treat
patients with risk factors. Another limitation is the sample
size of our study, which was relatively small, and could be
responsible for a lack of detection of some associations.
The present study was a secondary analysis of data col-
lected in a community-based randomized trial, and the num-
ber of patients included corresponds to the number of
patients included in the oseltamivir or zanamivir arms of the
Bivir therapeutic trial. The counterpart is that it allowed a
parallel assessment of the same factors, which were
recorded prospectively for the two drugs in exactly similar
conditions. It could explain why some factors already
known as inﬂuencing the response of oseltamivir have not
been found in our study. For instance ‘Time from the onset
of any symptoms to the start of treatment’, demonstrated
in several studies [9,29,30], has been tested as variable fac-
tor in our study, but was not associated with the response
for oseltamivir or zanamivir. The limitation is that subjects
in the Bivir trial were adults older than 18 years who con-
sulted their general practitioner and were included quickly
after the onset of the disease, within 36 h of inﬂuenza
symptoms onset.
Factors associated with a lower response to oseltamivir
or zanamivir appeared to be easily identiﬁable during routine
clinical examination and, when appropriate, by nasal sampling
at baseline. The association between gender and response to
oseltamivir, unknown until now, was not linked to the effect
of compliance. If it is conﬁrmed, other hypotheses remain to
be investigated.
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